concentration of 1 56 Mmol/l (123-2 Mg/l) in patients was not significantly different from that in controls (1I 63 ,umol/l (1 287 ,ug/l)). The difference in mean selenium concentration was largest and most significant for haematological malignancies alone. The difference in selenium concentrations in cases of fatal cancer compared with controls was significant (p < 0 01).
The risk of developing adenocarcinomas does not seem to be influenced by serum selenium concentration.
In recent years malignant morbidity and mortality have been observed to be somewhat higher in patients with low serum selenium concentrations prior to diagnosis. An inverse association with total cancer risk was found in four prospective studies ' Selenium concentrations were determined by electrothermal atomic absorption spectroscopy after dilution with a nickel matrix modifier according to the method of Saeed et al. 9 Specimens from each patient and matched control were randomly grouped into pairs and analysed sequentially in duplicate. Calibration was done against standards based on human serum known to contain selenium."' Quality assurance was ensured using a certified reference serum as a quality control." The coefficient of variation for the reference serum measured for every tenth specimen was 2 4%. The mean (SD) concentration of selenium in the reference serum was 1-16 (0-03) imol/l (91-6 (2-4) jg/l), while the proposed concentration was 1 15 (0.08) pmol/l (90-8 (6-3)pg/l)."
Statistical analyses were performed using the Statistical Package for the Social Sciences (SPSSX). 2 (table 3) .
The Cancer Registry also provides the opportunity to examine selenium concentrations in different his- tological groups.'3 14 As the case numbers were small, the only conclusion that can be drawn is that low serum selenium concentration does not seem to be associated with increased risk of development of adenocarcinoma. There were 26 cases of adenocarcinoma and the difference between cases and controls was 0-02 pmol/l (1 6 pg/l), 95% confidence interval = -0-10 to 0-14 imol/l. The relative risk for cancer in the lowest quartile (<1[45 gmol/l (1 14-5 yg/1)) of serum selenium concentration was 1-4 compared with higher serum selenium concentration (95% confidence interval = 0-6 -3 5). The estimate of relative risk was not changed significantly when the data were analysed without taking the matching into consideration and when adjusted by multiple logistic regression for the potential confounders of sex, age, smoking habit, total serum cholesterol concentration, systolic blood pressure, body mass index, and length of education.
Discussion
Our findings show that although serum selenium concentration was lower in cancer patients before diagnosis than it was in matched controls for most cancer sites, this was only significant for leukaemia. In agreement with a recent report,'5 we did not find any indications of a positive correlation between low serum selenium concentration and risk of breast cancer, nor did we find a significant difference for lung cancer, but there were only seven cases of lung cancer and the mean difference in serum selenium between these cases and controls was substantial (0 14 imol/l) 1 . I pg/1). 16 ' Considering that cancer is a heterogeneous group of diseases with different aetiologies, the possible protective effect of selenium may be more important for some cancers than for others. This may explain the findings in some studies which show that low serum selenium concentration protects against cancer in men but not in women.'34 The significant difference in serum selenium between patients who died and their matched controls may indicate that high selenium concentrations protect against certain cancers with a poor prognosis. Though there is some support for the present observations,23 the possibility that the significant differences seen for fatal and haematological cancers may be the result of chance, can not be excluded.
Few studies have examined serum selenium concentration in cancers ofdifferent histological groups. This is important when the aetiological relevance of selenium in carcinogenesis is considered. Though the interpretation ofour findings was hampered by a small number of cases, the results indicate that serum selenium has no bearing on the risk of adenocarcinoma (43% of the cancers in this study).
The difference between serum selenium concentrations in patients and controls was not significant in either men or women, but the p value for all cases was not very high (p = 010) and the mean difference between cases and controls (0 07 imol/l (5 5 yg/l)) did not differ greatly from the difference found in other prospective studies (0-09-0 13 Mmol/l (7-1-10-3 Mg/ 1))."' The insignificant difference in serum selenium between cases and controls for all cancers or some cancer sites (lung cancers) may, therefore, to some extent be due to lack of statistical power.
Stored sera from 12 (17%) of the cancer patients could not be analysed as they had been used for other research purposes. This underlines the need for the storage of several frozen serum aliquots.
The mechanisms proposed for anticarcinogenic effect of selenium include protection from oxidative damage from carcinogens, effects on carcinogen metabolism, and reduction in mutagenecity and toxicities of selenium metabolites to proliferating cells. '8'9 As the activity of the selenium dependent enzyme glutathione peroxidase tends to level out above selenium concentrations of 13 pmol/l (102 6 yg/l) in whole blood,' this may explain the stronger dose-response association between selenium and risk of cancer as seen in Finland, where the mean serum selenium concentration is lower than in Norway.5 21 The results from epidemiological studies have been inconclusive, and we still do not know whether increasing the intake of selenium reduces the risk of Serum selenium concentration associated with risk ofcancer 457 cancer in man. In future we advocate that less emphasis should be put on associations with total cancer incidence and that more emphasis should be placed on the associations between serum selenium and different types of cancers, both with regard to site and histological type. Trials of chemoprevention may provide definitive information on the possible anticarcinogenic effect of selenium, but such trials are difficult to perform as we do not know the optimal concentration of selenium supplement to be used, and because people have to be followed up long term.
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